> ## Content Index
> Fetch the complete content index at: https://www.tidemetrix.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Dishman secures commercial contract following US macrocyclic peptide launch
- URL: https://www.tidemetrix.com/dishman-secures-commercial-contract-following-us-macrocyclic-peptide-launch/
- Published: 2026-11-20T11:10:00.000Z
- Updated: 2026-11-21T11:11:44.000Z
- Description: Dishman's first commercial contract at its Naroda facility following the approval of a macrocyclic peptide drug marks an important step in establishing its presence in the commercial peptide supply chain.
- Author: TideMetrix Editorial
- Tags: Companies, India, #brief, Dishman Carbogen Amcis

India's Dishman Carbogen Amcis has secured its first commercial contract at its Naroda operation linked to a macrocyclic peptide drug following the product's US approval in July.

Speaking during a November 16 earnings call, in a transcript filed on November 20, management said manufacturing activities at Naroda had supported the product's US launch.

Management also revealed that another major pharmaceutical company had approached Dishman for similar manufacturing services, pointing to potential further business opportunities in the sector.

The company did not disclose the identity of the drug, the customer or the specific material being manufactured at Naroda. Contract value and production volumes were also undisclosed.

### Sources

- [Dishman Carbogen Amcis — November 16 earnings-call transcript, filed November 20, 2026, pp. 5–6](https://nsearchives.nseindia.com/corporate/DCAL%5F20112026191514%5FTranscriptofConCall20112026S.pdf?ref=tidemetrix.com)